Division of Chronic Disease Research Across the Lifecourse (CoRAL), Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
Applied Clinical Research Center, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pa.
Acad Pediatr. 2018 Jul;18(5):569-576. doi: 10.1016/j.acap.2018.02.008. Epub 2018 Mar 15.
The National Patient-Centered Clinical Research Network (PCORnet) supports observational and clinical research using health care data. The PCORnet Antibiotics and Childhood Growth Study is one of PCORnet's inaugural observational studies. We sought to describe the processes used to integrate and analyze data from children across 35 participating institutions, the cohort characteristics, and prevalence of antibiotic use.
We included children in the cohort if they had at least one same-day height and weight measured in each of 3 age periods: 1) before 12 months, 2) 12 to 30 months, and 3) after 24 months. We distributed statistical queries that each institution ran on its local version of the PCORnet Common Data Model, with aggregate data returned for analysis. We defined overweight or obesity as age- and sex-specific body mass index ≥85th percentile, obesity ≥95th percentile, and severe obesity ≥120% of the 95th percentile.
A total of 681,739 children met the cohort inclusion criteria, and participants were racially/ethnically diverse (24.9% black, 17.5% Hispanic). Before 24 months of age, 55.2% of children received at least one antibiotic prescription; 21.3% received a single antibiotic prescription; 14.3% received 4 or more; and 33.3% received a broad-spectrum antibiotic. Overweight and obesity prevalence was 27.6% at age 4 to <6 years (n = 362,044) and 36.2% at 9 to <11 years (n = 58,344).
The PCORnet Antibiotics and Childhood Growth Study is a large national longitudinal observational study in a diverse population that will examine the relationship between early antibiotic use and subsequent growth patterns in children.
国家以患者为中心的临床研究网络(PCORnet)支持使用医疗保健数据进行观察性和临床研究。PCORnet 抗生素和儿童生长研究是 PCORnet 的首批观察性研究之一。我们旨在描述整合和分析来自 35 个参与机构的儿童数据的过程、队列特征以及抗生素使用的普遍性。
我们纳入了至少在 3 个年龄阶段(1)12 个月前、2)12 至 30 个月和 3)24 个月后,每天测量身高和体重的儿童。我们分发了统计查询,每个机构都在其本地版本的 PCORnet 通用数据模型上运行,汇总数据进行分析。我们将超重或肥胖定义为特定年龄和性别的体重指数≥第 85 百分位数,肥胖≥第 95 百分位数,严重肥胖≥第 95 百分位数的 120%。
共有 681,739 名儿童符合队列纳入标准,参与者种族/民族多样化(24.9%黑人,17.5%西班牙裔)。在 24 个月之前,55.2%的儿童至少接受过一次抗生素处方;21.3%接受过单一抗生素处方;14.3%接受了 4 种或更多;33.3%接受了广谱抗生素。4 至<6 岁(n=362,044)和 9 至<11 岁(n=58,344)儿童的超重和肥胖患病率分别为 27.6%和 36.2%。
PCORnet 抗生素和儿童生长研究是一项在多样化人群中进行的大型全国性纵向观察性研究,将研究儿童早期抗生素使用与随后的生长模式之间的关系。